Wounds that are hard to heal are an increasing problem throughout the world. Millions of people suffer from them and treatment is both costly, time consuming and causes patients pain and discomfort.
Dative is a biotechnology research company that is developing two different technologies in order to produce a solution to this problem. One is the PolySel© - an absorbent gel formula which can be used together with various kind of active substances. The other is an antimicrobial compound containing nanosilver.
These two will combine to Ag+el©- an easy-to-use gel with significantly higher antimicrobial effect than competing products.
The market is today dominated by a few large players who market a wide range of wound care products based on various types of technologies. Dative’s primary customer segment is professional health care facilities such as hospitals, medical centers and units within the elderly care.
An agreement has been signed with Swedish med-tech company InterMed to market Ag+el© exclusively for three years. InterMed will receive a commission of 35% of all sales while Dative will focus on its core competencies, namely R&D and production. InterMed will also license in PolySel© and market it under own brand until the silver compound needed in Ag+el© is fully developed.
The calculated net present value of Dative is currently €2,23M. Potential investors will be offered a total of 30 % of Datives shares at a price of €750 000. ROI is calculated to be 40% in 7 years.
Table of Contents
1. Introducing Dative Research p. 1
2. The Business p. 2
-2.1 The Organization
-2.2 The Products; Ag+el© and PolySel©
3. The Market p. 4
-3.1 Market Type and Size
4. The Value of Ag+el© p. 7
5. Business Strategy p. 8
-5.1 Research and Development
-5.2 Production Plan
-5.3 Marketing Strategy